A Phase 1/2 interventional study of MK-1200 and Antiemetic in Advanced Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Completed at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1, participants will receive escalating doses of MK-1200 via intravenous (IV) infusion every 2 weeks (Q2W) until any discontinuation criteria are met.
Biological: MK-1200 · Drug: Antiemetic
In Part 2, participants in Cohort A will receive either Dose 1 or Dose 2 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.
Biological: MK-1200 · Drug: Antiemetic
In Part 2, participants in Cohort B will receive Dose 1 of MK-1200 (determined from Part 1) via IV infusion Q2W until any discontinuation criteria are met.
Biological: MK-1200 · Drug: Antiemetic
IV Infusion
One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1
The occurrence of any of the following toxicities within 28 days after the first dose of study intervention were considered a DLT, if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration: * Grade 4 nonhematologic toxicity (not laboratory). Any nonhematologic AE ≥Grade 3 in severity was considered a DLT, with pre-specified exceptions * Any Grade 3 or Grade 4 laboratory value (hematologic or nonhematologic), with pre-specified exceptions * Febrile neutropenia Grade 3 or Grade 4 as prespecified by the protocol * Prolonged delay (\>2 weeks) in initiating Cycle 2 due to intervention-related toxicity * Any intervention-related toxicity that caused the participant to discontinue intervention during Cycle 1 * Missed \>25% of MK-1200 doses as a result of drug-related AEs during the first cycle * Grade 5 toxicity
Time frame: During the first two 14-day cycles (Up to approximately 28 days)
Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is reported for each arm.
Time frame: Up to approximately 12 months
Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study intervention due to an AE is reported for each arm.
Time frame: Up to approximately 9 months
Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) - Part 2 Cohort A
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). As pre-specified by the protocol, this analysis was to only include all participants randomized to Part 2 Cohort A who received at least 1 dose of study intervention.
Time frame: Up to approximately 13 months
ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator.
Time frame: Up to approximately 13 months
Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2
AUC0-336 was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine the AUC0-336 of the MK-1200-ADC.
Time frame: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2
AUC0-336 was defined as the area under the concentration versus time curve of KL610023 from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine AUC0-336 of KL610023.
Time frame: Cycle 1 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2
AUC0-tau was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of the MK-1200-ADC.
Time frame: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
AUC0-tau of KL610023 - Parts 1 and 2
AUC0-tau is defined as the area under the concentration versus time curve of KL610023 from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of KL610023.
Time frame: Cycle 4 Day 1: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Minimum Concentration (Cmin) of MK-1200-ADC - Part 1 & Part 2
Cmin was defined as the minimum concentration of MK-1200-ADC observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of the MK-1200-ADC.
Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmin of KL610023 - Part 1 & Part 2
Cmin was defined as the minimum concentration of KL610023 observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of KL610023.
Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Maximum Concentration (Cmax) of MK-1200-ADC - Part 1 & Part 2
Cmax was defined as the maximum or 'peak' concentration of MK-1200-ADC observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of the MK-1200-ADC.
Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Cmax of KL610023 - Part 1 & Part 2
Cmax was defined as the maximum or 'peak' concentration of KL610023 observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of KL610023.
Time frame: Day 1 of Cycles 1 and 4: predose and 0.5, 2, 4, 8, 24, 72, 168, 240, and 336 hours postdose. A cycle was 14 days.
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from the first documented evidence of a CR or a PR until Progressive Disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, DOR for Part 2 Cohort A was planned to be assessed by BICR and was to include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
Time frame: Up to approximately 13 months
DOR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from the first documented evidence of a CR or a PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator is reported.
Time frame: Up to approximately 13 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR - Part 2 Cohort A
PFS was defined as the time from randomization to the first documented PD by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, PFS for Part 2 Cohort A was planned to be assessed by BICR and was to only include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
Time frame: Up to approximately 13 months
PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B
PFS was defined as the time from randomization to the first documented PD by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by the investigator is reported.
Time frame: Up to approximately 13 months
Overall Survival (OS) - Part 1 & Part 2
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 13 months
| Milestone | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Started | 3 | 5 | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 5 | 5 | 0 | 0 |
| Withdrew: Death | 2 | 5 | 4 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
The occurrence of any of the following toxicities within 28 days after the first dose of study intervention were considered a DLT, if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration: * Grade 4 nonhematologic toxicity (not laboratory). Any nonhematologic AE ≥Grade 3 in severity was considered a DLT, with pre-specified exceptions * Any Grade 3 or Grade 4 laboratory value (hematologic or nonhematologic), with pre-specified exceptions * Febrile neutropenia Grade 3 or Grade 4 as prespecified by the protocol * Prolonged delay (\>2 weeks) in initiating Cycle 2 due to intervention-related toxicity * Any intervention-related toxicity that caused the participant to discontinue intervention during Cycle 1 * Missed \>25% of MK-1200 doses as a result of drug-related AEs during the first cycle * Grade 5 toxicity
| Participants | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1 | 0 | 0 | 1 | — | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE is reported for each arm.
| Participants | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2 | 3 | 5 | 5 | — | — |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study intervention due to an AE is reported for each arm.
| Participants | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2 | 0 | 0 | 0 | — | — |
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by blinded independent central review (BICR). As pre-specified by the protocol, this analysis was to only include all participants randomized to Part 2 Cohort A who received at least 1 dose of study intervention.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator.
| Percentage of Participants | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| ORR Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B | 0 (0.0 to 70.8) | 0 (0.0 to 52.2) | 0 (0.0 to 52.2) | — | — |
AUC0-336 was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine the AUC0-336 of the MK-1200-ADC.
| hr*μg/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to 336 Hours (AUC0-336) of MK-1200-Antibody-Drug Conjugate (ADC) - Parts 1 and 2 | 2840 ± 49.7 | 4310 ± 40.9 | 3770 ± 24.5 | — | — |
AUC0-336 was defined as the area under the concentration versus time curve of KL610023 from time 0 to 336 Hours. Blood samples were collected at pre-specified timepoints to determine AUC0-336 of KL610023.
| hr*ng/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| AUC0-336 of the Conjugated Toxin Payload (KL610023) - Parts 1 and 2 | 329 ± 40.8 | 748 ± 18.9 | 583 ± 173.9 | — | — |
AUC0-tau was defined as the area under the concentration versus time curve of MK-1200-ADC from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of the MK-1200-ADC.
| hr*μg/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Period (AUC0-tau) of MK-1200-ADC - Parts 1 and 2 | 3130 ± 40.3 | 4070 ± 35.8 | 2580 ± NA | — | — |
AUC0-tau is defined as the area under the concentration versus time curve of KL610023 from time 0 to the end of the 14-day dosing period (Cycle 4, 336 hours post-dose). Blood samples were collected at pre-specified timepoints to determine AUC0-tau of KL610023.
| hr*ng/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| AUC0-tau of KL610023 - Parts 1 and 2 | 319 ± 25.9 | 723 ± 19.9 | 308 ± NA | — | — |
Cmin was defined as the minimum concentration of MK-1200-ADC observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of the MK-1200-ADC.
| μg/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.176 ± 67.4 | NA ± NA | NA ± NA | — | — |
| Cycle 4 Day 1 | NA ± NA | 0.167 ± 64.7 | 0.390 ± NA | — | — |
Cmin was defined as the minimum concentration of KL610023 observed in plasma after its administration and just prior to administration of a subsequent dose. Blood samples were collected at pre-specified timepoints to determine Cmin of KL610023.
| ng/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | — | — |
| Cycle 4 Day 1 | NA ± NA | NA ± NA | NA ± NA | — | — |
Cmax was defined as the maximum or 'peak' concentration of MK-1200-ADC observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of the MK-1200-ADC.
| μg/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 60.5 ± 34.2 | 89.0 ± 42.9 | 73.7 ± 13.3 | — | — |
| Cycle 4 Day 1 | 68.1 ± 18.2 | 84.7 ± 36.3 | 70.7 ± NA | — | — |
Cmax was defined as the maximum or 'peak' concentration of KL610023 observed after its administration. Blood samples were collected at pre-specified timepoints to determine Cmax of KL610023.
| ng/mL | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 6.26 ± 49.4 | 12.0 ± 21.6 | 15.8 ± 85.2 | — | — |
| Cycle 4 Day 1 | 6.50 ± 31.1 | 15.5 ± 55.3 | 3.64 ± NA | — | — |
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from the first documented evidence of a CR or a PR until Progressive Disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, DOR for Part 2 Cohort A was planned to be assessed by BICR and was to include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
No measurements were reported for this outcome.
For participants demonstrating a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from the first documented evidence of a CR or a PR until PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator is reported.
No measurements were reported for this outcome.
PFS was defined as the time from randomization to the first documented PD by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. As pre-specified by the protocol, PFS for Part 2 Cohort A was planned to be assessed by BICR and was to only include all participants randomized to Part 2 Cohort A who received at least one dose of study intervention.
No measurements were reported for this outcome.
PFS was defined as the time from randomization to the first documented PD by investigator or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by the investigator is reported.
| Months | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| PFS Per RECIST 1.1 as Assessed by Investigator - Part 1 & Part 2 Cohort B | 2.9 (2.6 to NA) | 3.9 (1.5 to NA) | 1.3 (0.4 to NA) | — | — |
OS was defined as the time from randomization to death due to any cause.
| Months | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) |
|---|---|---|---|---|---|
| Overall Survival (OS) - Part 1 & Part 2 | 8.4 (4.1 to NA) | 4.6 (3.4 to NA) | 3.7 (1.6 to NA) | — | — |
Collected over Up to approximately 13 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MK-1200 3.6 mg/kg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: MK-1200 4.2 mg/kg | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Part 1: MK-1200 4.8 mg/kg | 4/5 (80%) | 0/5 (0%) | 5/5 (100%) |
| Event | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg |
|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 2/5 | 0/5 |
| Biliary obstructionHepatobiliary disorders | 1/3 | 0/5 | 0/5 |
| Device occlusionProduct Issues | 1/3 | 0/5 | 0/5 |
| AscitesGastrointestinal disorders | 0/3 | 1/5 | 0/5 |
| SepsisInfections and infestations | 0/3 | 1/5 | 0/5 |
| EmbolismVascular disorders | 0/3 | 1/5 | 0/5 |
| Event | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/3 | 2/5 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 4/5 | 0/5 |
| FatigueGeneral disorders | 1/3 | 3/5 | 4/5 |
| Abdominal painGastrointestinal disorders | 2/3 | 1/5 | 0/5 |
| DizzinessNervous system disorders | 2/3 | 0/5 | 0/5 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 3/5 | 1/5 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 2/5 | 1/5 |
| AscitesGastrointestinal disorders | 0/3 | 2/5 | 0/5 |
| VomitingGastrointestinal disorders | 0/3 | 2/5 | 2/5 |
| AstheniaGeneral disorders | 0/3 | 2/5 | 0/5 |
Baseline characteristics include data from 13 participants allocated to Part 1. No participants were enrolled in Part 2; therefore, no baseline characteristics data are reported for Part 2.
| Age, Continuous(Years) | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) | Total |
|---|---|---|---|---|---|---|
| Mean | 63.7 ± 13.6 | 64.0 ± 8.7 | 62.0 ± 8.3 | — | — | 63.2 ± 8.9 |
| Sex: Female, Male(Participants) | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 5 | 0 | 0 | 0 | 6 |
| Male | 2 | 0 | 5 | 0 | 0 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 0 | 2 |
| Not Hispanic or Latino | 3 | 4 | 4 | 0 | 0 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: MK-1200 3.6 mg/kg | Part 1: MK-1200 4.2 mg/kg | Part 1: MK-1200 4.8 mg/kg | Part 2: MK-1200 Cohort A (Part 2-Not Enrolled) | Part 2: MK-1200 Cohort B (Part 2-Not Enrolled) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 5 | 5 | 0 | 0 | 13 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2024 to primary completion in Jun 2025, 15 months.
Results were first posted in Jun 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200